PL370459A1 - Retynoidowi agoniści II typu podstawionego mocznika - Google Patents
Retynoidowi agoniści II typu podstawionego mocznikaInfo
- Publication number
- PL370459A1 PL370459A1 PL02370459A PL37045902A PL370459A1 PL 370459 A1 PL370459 A1 PL 370459A1 PL 02370459 A PL02370459 A PL 02370459A PL 37045902 A PL37045902 A PL 37045902A PL 370459 A1 PL370459 A1 PL 370459A1
- Authority
- PL
- Poland
- Prior art keywords
- substituted urea
- cancer
- emphysema
- retinoid agonists
- dermatological disorders
- Prior art date
Links
- 239000000556 agonist Substances 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- -1 urea retinoid Chemical class 0.000 title 1
- 206010014561 Emphysema Diseases 0.000 abstract 3
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 201000011510 cancer Diseases 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- 241000124008 Mammalia Species 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C275/00—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups
- C07C275/28—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
- C07C275/42—Derivatives of urea, i.e. compounds containing any of the groups, the nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of urea groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton being further substituted by carboxyl groups
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
- C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
- C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
- C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
- C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Compounds Containing Sulfur Atoms (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32296201P | 2001-09-18 | 2001-09-18 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| PL370459A1 true PL370459A1 (pl) | 2005-05-30 |
| PL209697B1 PL209697B1 (pl) | 2011-10-31 |
Family
ID=23257206
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL370459A PL209697B1 (pl) | 2001-09-18 | 2002-09-11 | Pochodne mocznika, środek farmaceutyczny i zastosowanie pochodnych mocznika |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US6838472B2 (pl) |
| EP (1) | EP1430023B1 (pl) |
| JP (1) | JP4410562B2 (pl) |
| KR (1) | KR100891224B1 (pl) |
| CN (1) | CN1301968C (pl) |
| AR (1) | AR036532A1 (pl) |
| AT (1) | ATE427929T1 (pl) |
| AU (1) | AU2002340886B2 (pl) |
| BR (1) | BR0212607A (pl) |
| CA (1) | CA2458266C (pl) |
| DE (1) | DE60231888D1 (pl) |
| ES (1) | ES2325063T3 (pl) |
| MX (1) | MXPA04002305A (pl) |
| PL (1) | PL209697B1 (pl) |
| RU (1) | RU2303027C2 (pl) |
| WO (1) | WO2003024920A1 (pl) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1889830A1 (en) | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | Biarylcarboxyarylamides as vanilloid-1 receptor modulators |
| EP1889837A1 (en) * | 2006-07-10 | 2008-02-20 | Pharmeste S.r.l. | VR1 vanilloid receptor antagonists with a iononic substructure |
| PL2613776T3 (pl) | 2010-09-01 | 2021-01-11 | Thomas Jefferson University | Kompozycja oraz sposób naprawy i regeneracji mięśni |
| CN109589324B (zh) | 2012-11-08 | 2022-06-14 | 国立大学法人山口大学 | 角结膜病症的治疗剂 |
| CN105377258B (zh) | 2013-05-22 | 2020-08-28 | 国立大学法人山口大学 | 视网膜脉络膜病症的抑制剂 |
| ES2963348T3 (es) | 2016-06-08 | 2024-03-26 | Clementia Pharmaceuticals Inc | Métodos para tratar la osificación heterotópica |
| BR112019009929A2 (pt) | 2016-11-16 | 2019-08-20 | Clementia Pharmaceuticals Inc | métodos para inibir a formação de um osteocondroma, para reduzir o tamanho de um osteocondroma, para desacelerar o crescimento de um osteocondroma e para reduzir hiperplasia de cartilagem |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| LU87821A1 (fr) | 1990-10-12 | 1992-05-25 | Cird Galderma | Composes bi-aromatiques,et leur utilisation en medecine humaine et veterinaire et en cosmetique |
| HUT62558A (en) * | 1991-07-01 | 1993-05-28 | Sandoz Ag | Process for producing n-phenylthiourea derivaties and pharmaceutical compositions comprising same |
| US5648514A (en) * | 1994-12-29 | 1997-07-15 | Allergan | Substituted acetylenes having retinoid-like biological activity |
| US5599967A (en) * | 1994-12-29 | 1997-02-04 | Allergan | Acetylenes disubstituted with a 5 substituted tetrahydronaphthyl group and with an aryl of heteroaryl group having retinoid-like biological activity |
| US6093742A (en) | 1997-06-27 | 2000-07-25 | Vertex Pharmaceuticals, Inc. | Inhibitors of p38 |
| JO2178B1 (en) | 1999-10-19 | 2003-04-23 | اف . هوفمان لاروش ايه جي | Treatment of emphysema using rar selective retinoid antagonists |
-
2002
- 2002-09-11 PL PL370459A patent/PL209697B1/pl not_active IP Right Cessation
- 2002-09-11 WO PCT/EP2002/010181 patent/WO2003024920A1/en not_active Ceased
- 2002-09-11 ES ES02774599T patent/ES2325063T3/es not_active Expired - Lifetime
- 2002-09-11 RU RU2004111789/04A patent/RU2303027C2/ru not_active IP Right Cessation
- 2002-09-11 EP EP02774599A patent/EP1430023B1/en not_active Expired - Lifetime
- 2002-09-11 JP JP2003528768A patent/JP4410562B2/ja not_active Expired - Fee Related
- 2002-09-11 KR KR1020047003921A patent/KR100891224B1/ko not_active Expired - Fee Related
- 2002-09-11 BR BR0212607-9A patent/BR0212607A/pt not_active IP Right Cessation
- 2002-09-11 CA CA2458266A patent/CA2458266C/en not_active Expired - Fee Related
- 2002-09-11 AT AT02774599T patent/ATE427929T1/de active
- 2002-09-11 DE DE60231888T patent/DE60231888D1/de not_active Expired - Lifetime
- 2002-09-11 AU AU2002340886A patent/AU2002340886B2/en not_active Ceased
- 2002-09-11 MX MXPA04002305A patent/MXPA04002305A/es active IP Right Grant
- 2002-09-11 CN CNB028178327A patent/CN1301968C/zh not_active Expired - Fee Related
- 2002-09-16 AR ARP020103489A patent/AR036532A1/es not_active Application Discontinuation
- 2002-09-17 US US10/244,885 patent/US6838472B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| CA2458266C (en) | 2011-03-15 |
| CN1555357A (zh) | 2004-12-15 |
| KR20040035808A (ko) | 2004-04-29 |
| AR036532A1 (es) | 2004-09-15 |
| ATE427929T1 (de) | 2009-04-15 |
| AU2002340886B2 (en) | 2008-01-31 |
| CA2458266A1 (en) | 2003-03-27 |
| US20030125383A1 (en) | 2003-07-03 |
| JP2005503411A (ja) | 2005-02-03 |
| CN1301968C (zh) | 2007-02-28 |
| PL209697B1 (pl) | 2011-10-31 |
| EP1430023B1 (en) | 2009-04-08 |
| JP4410562B2 (ja) | 2010-02-03 |
| DE60231888D1 (de) | 2009-05-20 |
| RU2004111789A (ru) | 2005-10-20 |
| KR100891224B1 (ko) | 2009-04-01 |
| BR0212607A (pt) | 2004-08-17 |
| WO2003024920A1 (en) | 2003-03-27 |
| RU2303027C2 (ru) | 2007-07-20 |
| MXPA04002305A (es) | 2004-06-29 |
| ES2325063T3 (es) | 2009-08-25 |
| US6838472B2 (en) | 2005-01-04 |
| EP1430023A1 (en) | 2004-06-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2434B1 (en) | New retinoids to treat emphysema | |
| AU2003256755A1 (en) | Ureido substituted benzoic acid compounds, their use for nonsense suppression and the treatment of diseases caused by such mutations | |
| MXPA03011515A (es) | Nuevas composiciones de medicamentos sobre la base de agentes anticolinergicos, corticoesteroides y agentes betamimeticos. | |
| MXPA04002070A (es) | Compuestos de indazol sustituidos para el tratamiento de la inflamacion. | |
| MY141661A (en) | 17b-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases | |
| WO2002100347A3 (en) | Prodrugs of gaba analogs, compositions and uses thereof | |
| IL162214A (en) | Pyridine derivatives and pharmaceutical compositions containing the same | |
| MXPA04008068A (es) | Metodo para administrar moleculas de glp-1. | |
| WO2004043341A3 (en) | Treatment for hemorrhagic shock | |
| MXPA03008135A (es) | Combinacion de analogos de epotilona y agentes quimioterapeuticos para tratamiento de enfermedades proliferativas. | |
| MXPA03010761A (es) | Combinaciones farmaceuticas. | |
| MY141528A (en) | Anilinopyrazole derivatives useful for the treatment of diabetes | |
| GB0002336D0 (en) | Medicaments | |
| PL370361A1 (pl) | Retynoidowi agoniści I typu alkilomocznika | |
| EP1420827B8 (en) | 5-cnac as oral delivery agent for parathyroid hormone fragments | |
| AU4179399A (en) | Use of nmda antagonists and/or sodium channel antagonists for the treatment of inflammatory disorders | |
| WO2004073615A8 (en) | Deazaflavin compounds and methods of use thereof | |
| DE69917005D1 (de) | Substituierte pyrrolobenzimidazolderivate zur entzündungshemmung | |
| WO2002041831A3 (en) | Inositol derivatives for increasing chloride secretion and inhibiting inflammation | |
| MXPA02007903A (es) | Uso de acido 2-metil-tiazolidina-2, 4-dicarboxilico (2-mtdc) y/o sales fisiologicamente compatibles para tratar y/o prevenir canceres. | |
| IL168308A (en) | Compositions containing roflumilast and formoterol | |
| BR0212607A (pt) | Agonistas retinóides ii de uréia substituìda | |
| WO2002096870A3 (en) | Sponge-derived terpenoids and methods of use | |
| WO2003094967A3 (en) | New combination of reversible proton pump inhibitors and airway therapeutics for treating airway disorders | |
| UA83017C2 (uk) | Комбінація рофлуміласту та r,r-формотеролу для лікування захворювань дихальних шляхів |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Decisions on the lapse of the protection rights |
Effective date: 20120911 |